Clicky

  • Login
  • Register
  • Submit Your Content
  • Contact Us
Monday, November 4, 2024
World Tribune
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
Submit
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
No Result
View All Result
World Tribune
No Result
View All Result

From Australia to the world: democratising data to better understand IBD

March 5, 2024
in Health
Reading Time: 5 mins read
A A
From Australia to the world: democratising data to better understand IBD
0
SHARES
ShareShareShareShareShare

From Australia to the world: democratising data to better understand IBD

Australia-based not-for-profit organisation Crohn’s Colitis Cure (CCCure) has recently launched subscription-based access to its registry of data on patients dealing with inflammatory bowel diseases.

The IBD-focused charity claims to have one of the world’s largest databases of real-time patient-reported and clinical data on IBD, including Crohn’s disease, ulcerative colitis, and IBD-undetermined.

WHAT IT DOES

Its clinical management system, Crohn’s Colitis Care (CCCare), features IBD-specific EMR that facilitates care documentation in near real-time. Holding the largest structured dataset in Australia, it has approximately 300 clinical users and 14,500 patient records, representing over 45,000 clinical encounters and about 30,000 patient years. Introduced in 2018, the EMR is available at the point of care and continually refreshes with every patient and clinician interaction. Additionally, it can be used as a guided practice tool, unlike generic EMRs, CCCure claims.

The system also features a consumer portal where patients can self-report and share their health information with clinical teams. 

Operating as a stand-alone, cloud-based system that is accessible via web browsers, CCCare can generate care plans and consultation letters, which can be uploaded to other clinical management systems or emailed to clinicians anywhere. 

Patient-reported and clinical data are also linked to a clinical quality registry (CQR) where it is automatically de-identified/anonymised. Work is in progress to include biological data in the system. 

CCCare is now used in over 20 IBD clinics in Australia and New Zealand with 10 more in the process of onboarding. It is also being evaluated for adoption in healthcare settings in the United States, Europe, Japan, and the United Arab Emirates.

Recently, CCCure partnered with major pathology vendors to enable the live integration of pathology results into CCCare. The company is also arranging the data output to the Australian government’s My Health Record and direct EMR integrations with major hospitals. 

WHY IT MATTERS

Cases of IBD are on the rise. In 2019, nearly five million people were living with the disease, jumping from three million over the past 30 years. Within the same period, cases in Asia showed an increasing trend.

With no known cure, IBD patients will require specialist, multidisciplinary care – and for a lifetime. Efforts have been rolling to find personalised, targeted and effective therapies for IBD. For CCCure CEO Bill Petch, the key to this is access to real-world IBD data and insights. 

“IBD is emerging in parts of the world and demographics it has never been seen before, so equity of access to proven therapies and the need for a more personal, patient-focused approach to care is crucial, in Australia, New Zealand, and globally,” he said. In Australia, the disease may affect up to 300,000 people by 2030. 

CCCare, Petch continues, can provide “insights that would normally be difficult and costly to access.” “Rather than keeping it locked away, we’ve opened it up so we can improve IBD care right now.”

As it opens its big database to the world, CCCure employs a range of measures to protect patient and clinical data, including multi-factor authentication, role-based security, Azure Active Directory integration, HTTPS access, row-level security, dynamic data masking, transparent data encryption, and comprehensive logging and reporting of user actions. It also has geolocated cloud storage, undergoes annual penetration testing, and segments identifiable data from sites. Moreover, it has strict protocols to detect unusual usage patterns.

The company is currently in advanced discussions with commercial partners and hospitals around the world for a subscription to its IBD registry. A major pharmaceutical company recently made the first subscription to CCCare data for R&D. 

MARKET SNAPSHOT

Initiatives have been made across the world to transform data into insights that will lead to more effective strategies for managing IBD. Israeli startup CytoReason, for instance, has partnered with Swiss pharma Ferring Pharmaceuticals to find new treatments for IBD. They are building cell-centred disease models powered by CytoReason’s AI and leveraging public and proprietary molecular data to address IBD at the cellular level.

Meanwhile, CCCure acknowledges the potential of its “versatile” clinical management system to be adapted to other disease pathways in the future. “[W]hile our focus remains on optimising IBD care, we recognise the potential for our model to extend its impact to other healthcare domains in the long term.”

ON THE RECORD

“Real-time access to data and insights is pivotal in revolutionising IBD management towards personalised and targeted approaches. The conventional timeline of approximately 17 years for research to translate into routine care is impractical for patients needing optimal care today. CCCare’s approach, with its continuous audit output, accelerates the integration of cutting-edge knowledge into clinical practice, empowering healthcare providers to deliver more effective and tailored care immediately. This not only enhances the quality of care for individuals with IBD but also advances our collective journey towards finding a cure. The urgency of optimising care now and being instrumental in the pursuit of a cure underscores the significance of real-time data accessibility in transforming IBD management,” said Jane Mary Andrews, board chair of CCCure and clinical professor at the University of Adelaide School of Medicine.

Credit: Source link

READ ALSO

Medtronic issues voluntary recall of MiniMed insulin pumps

Hybrid primary care company Rezilient Health scores $10M

ShareTweetSendSharePin
Previous Post

Top economist says it will be years before housing market unfreezes

Next Post

China may have to resort to a tried-and-tested tactic to power its ‘new leap forward’

Related Posts

Medtronic issues voluntary recall of MiniMed insulin pumps
Health

Medtronic issues voluntary recall of MiniMed insulin pumps

October 4, 2024
Hybrid primary care company Rezilient Health scores M
Health

Hybrid primary care company Rezilient Health scores $10M

October 4, 2024
Empathy Health Technologies raises .8M for Sober Sidekick app
Health

Empathy Health Technologies raises $2.8M for Sober Sidekick app

October 4, 2024
Indian mental health app Lissun takes on AI with M and more briefs
Health

Indian mental health app Lissun takes on AI with $3M and more briefs

October 4, 2024
Virtual dementia care platform Rippl scores M
Health

Virtual dementia care platform Rippl scores $23M

October 3, 2024
Royal Philips unveils smart baby monitor
Health

Royal Philips unveils smart baby monitor

October 3, 2024
Next Post
China may have to resort to a tried-and-tested tactic to power its ‘new leap forward’

China may have to resort to a tried-and-tested tactic to power its 'new leap forward'

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

What's New Here!

Eero launches a weatherproof extender for outdoor Wi-Fi

Eero launches a weatherproof extender for outdoor Wi-Fi

October 23, 2024
What supply disruption could mean for oil markets

What supply disruption could mean for oil markets

October 8, 2024
OpenAI says more cyber actors using its platform to disrupt elections

OpenAI says more cyber actors using its platform to disrupt elections

October 10, 2024
German finance minister warns of retaliation if U.S. kicks off trade war

German finance minister warns of retaliation if U.S. kicks off trade war

October 25, 2024
MicroStrategy soars 6% to hit highest stock price since March

MicroStrategy soars 6% to hit highest stock price since March

October 8, 2024
How to use a VPN on Fire TV for streaming

How to use a VPN on Fire TV for streaming

October 18, 2024
Flying cars are finally going to happen: The FAA just created the first new aircraft category in 80 years

Flying cars are finally going to happen: The FAA just created the first new aircraft category in 80 years

October 22, 2024

About

World Tribune is an online news portal that shares the latest news on world, business, health, tech, sports, and related topics.

Follow us

Recent Posts

  • Searches soar as travelers look for discounts
  • Kamala Harris won’t say how she voted on California crime measure
  • Nets’ momentum comes to crashing halt with loss to Pistons
  • Chris Olave carted off with second concussion of season after scary hit

Newslatter

Loading
  • Submit Your Content
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2024 World Tribune - All Rights Reserved!

No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food

© 2024 World Tribune - All Rights Reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In